CancerRadarCancerRadar
RadiopharmaceuticalFDA-approvedSecond-line

Lutetium-177 vipivotide tetraxetan

How it works

Delivers targeted radiation to prostate cancer cells, causing cell death.

Cancer types

Prostate Cancer

Efficacy

Studies show that lutetium-177 vipivotide tetraxetan can improve overall survival in patients with advanced prostate cancer.

Side effects

Severe

This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.

This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.